Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Sepimostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 3/20 | 0.62 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.59 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.59 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.59 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.59 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.59 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.59 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.59 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.59 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.59 |
| ▸ | GHSR known ✓ | Q92847 | 1/20 | 0.59 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.70 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.62 |
| ▸ | F10 | P00742 | 3/20 | 0.62 |
| ▸ | KLK1 | P06870 | 3/20 | 0.62 |
| ▸ | C1R | P00736 | 2/20 | 0.62 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.62 |
| ▸ | F12 | P00748 | 11/20 | 0.59 |
| ▸ | HGFAC | Q04756 | 2/20 | 0.59 |
| ▸ | PLG | P00747 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sepimostat SCHEMBL15535526 | 0.94 | F12 (0.67) | FTOPRSS1F2F10KLK1 | |
| Nafamostat SCHEMBL25197320 | 0.83 | FTO (1.00) | FTOPRSS1F2F10KLK1 | |
| Nafamostat SCHEMBL1650158 | 0.83 | FTO (1.00) | FTOPRSS1F2F10KLK1 | |
| SCHEMBL7340875 | 0.80 | FTO (0.74) | FTOPRSS1F2F10KLK1 | |
| SCHEMBL10922456 | 0.80 | FTO (0.74) | FTOPRSS1F2F10KLK1 | |
| Nafamostat SCHEMBL1568755 | 0.77 | FTO (0.70) | FTOPRSS1F2F10KLK1 | |
| SCHEMBL7347942 | 0.77 | FTO (0.70) | FTOPRSS1F2F10KLK1 | |
| Nafamostat SCHEMBL564665 | 0.77 | FTO (0.70) | FTOPRSS1F2F10KLK1 | |
| Nafamostat SCHEMBL29832433 | 0.77 | FTO (0.70) | FTOPRSS1F2F10KLK1 | |
| SCHEMBL7345696 | 0.77 | FTO (0.70) | FTOPRSS1F2F10KLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | NIH - DEITR | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | PNLIP, LIPE, LIPC | F2 2200/4885CHRM1 4682/4885DRD2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.